Myelodysplastic Syndromes, Myeloid Leukemia
Conditions
Keywords
IFN-α, Preventing relapse, allo-HSCT
Brief summary
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Interventions
DRUGIFN-Α
Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
Sponsors
Peking University People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Myelodysplastic syndrome (MDS) diagnosed according to the 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemia (2022ICC) criteria, acute myeloid leukemia (AML) with TP53 mutation (unrestricted remission status), minimal residual disease (MRD) monitored by flow cytometry within 2 months after receiving the first allogeneic hematopoietic stem cell transplantation Negative patients 2. Male or female, aged 12-65 years 3. Karnofsky score \>60, estimated survival time \>3 months 4. No history of severe graft-versus-host disease (GVHD), uncontrolled GVHD, or severe systemic organ dysfunction: 1. Absolute neutrophil count (ANC) greater than 0.5×109/L 2. Creatinine \< 1.5mg/dL 3. Cardiac ejection index \>55% 5. Signed informed consent.
Exclusion criteria
1. severe cardiac, renal, or liver dysfunction 2. combined with other malignant tumors requiring treatment 3. inability to understand or adhere to the study protocol due to clinical symptoms of brain dysfunction or severe mental illness 4. patients who are unable to complete the necessary treatment plan and follow-up observation 5. patients with severe acute anaphylaxis 6. clinically uncontrolled severe life-threatening infections 7. patients enrolled in other clinical trials 8. other reasons considered by the investigator to be inappropriate for clinical trial participants.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of relapse | 1 year post HSCT | Disease relapse was defined as blasts ≥ 5% post transplantation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of positive minimal residual disease post allo-HSCT | 1 year post HSCT | Positive MRD was defined as leukemia-associated immunophenotyping (LAIPs) by flow cytometry. |
| The incidence of acute and chronic graft versus host disease (GvHD) | aGvHD within 100 days and cCvHD within 1 year | The severity of acute GvHD (aGvHD) and chronic GvHD (cGvHD) was evaluated according to standard criteria. |
| The incidence of non-relapse mortality | 1 year post HSCT. | The incidence of non-relapse mortality |
| The probability of progression free survival | 1 year post HSCT. | Survival without disease progression |
| The probability of overall survival (OS) | 1 year post HSCT. | OS was defined as the time from transplantation to death from any cause or to the last follow-up. |
Countries
China
Contacts
Primary ContactYu Wang
Outcome results
None listed